What is Cavion?
Headquartered in Charlottesville, Virginia, and Cambridge, Massachusetts, Cavion operates at the intersection of neuroscience and pharmaceutical innovation. The company specializes in the development of T-type calcium channel modulators, a therapeutic class designed to restore natural neurological rhythms. By targeting the underlying mechanisms of chronic and rare diseases, Cavion addresses critical unmet needs in patients suffering from essential tremor, Parkinson's disease tremor, neuropathic pain, and epilepsy with absence seizures.
The company's market position is defined by its rigorous scientific approach to drug discovery and its ability to attract top-tier institutional backing. As a clinical-stage entity, Cavion has demonstrated the efficacy of its platform, leading to its eventual integration as a wholly-owned subsidiary of Jazz Pharmaceuticals. This transition underscores the commercial viability of its pipeline and the strategic importance of its intellectual property in the global neurology market.
How much funding has Cavion raised?
Cavion has raised a total of $31.5M across 2 funding rounds:
Private Equity
$5M
Series A
$26.5M
Private Equity (2015): $5M, investors not publicly disclosed
Series A (2017): $26.5M led by Enso Ventures, Lilly Ventures, and Novartis Venture Fund
Key Investors in Cavion
Enso Ventures
Enso Ventures is a venture capital firm that specializes in making selective investments in groundbreaking, high-technology and bio-tech companies. The firm provides capital along with leadership and industry expertise with a clear focus on technology acceleration and commercial development.
Lilly Ventures
Lilly Ventures leverages the scientific tradition of Eli Lilly and Company to seek out compelling life science innovations. They partner actively with management teams to provide both financial and intellectual resources to accelerate the path to success.
Novartis Venture Fund
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications. Their venture arm focuses on research and development of treatments across multiple therapeutic areas to address various medical conditions.
What's next for Cavion?
Following its acquisition, the strategic focus for the Cavion portfolio shifts toward the integration of its T-type calcium channel modulators into a larger commercial framework. The capital previously raised has provided the necessary runway to transition from early-stage research to advanced clinical development. Moving forward, the emphasis will remain on optimizing therapeutic outcomes for patients with neurological disorders while leveraging the parent company's global infrastructure to scale manufacturing and distribution.
The successful execution of this roadmap will likely serve as a benchmark for future biotech ventures seeking to bridge the gap between academic discovery and clinical application. By maintaining a focus on high-growth market segments and disruptive technology platforms, the organization is well-positioned to influence the future of neurological treatment paradigms.
